Eyepoint Pharmaceuticals, Inc. $EYPT Shares Sold by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC trimmed its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 43.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 14,250 shares of the company’s stock after selling 11,000 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Eyepoint Pharmaceuticals were worth $134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in EYPT. GAMMA Investing LLC increased its position in shares of Eyepoint Pharmaceuticals by 3,174.4% in the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock valued at $56,000 after acquiring an additional 9,936 shares during the period. Arizona State Retirement System increased its position in shares of Eyepoint Pharmaceuticals by 12.7% in the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company’s stock valued at $90,000 after acquiring an additional 1,877 shares during the period. New York State Common Retirement Fund increased its position in shares of Eyepoint Pharmaceuticals by 208.8% in the 1st quarter. New York State Common Retirement Fund now owns 20,114 shares of the company’s stock valued at $109,000 after acquiring an additional 13,600 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at $114,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Eyepoint Pharmaceuticals by 62.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,571 shares of the company’s stock valued at $122,000 after acquiring an additional 8,676 shares during the period. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Stock Down 2.9%

NASDAQ:EYPT opened at $13.57 on Friday. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $14.91. The stock has a market capitalization of $935.34 million, a PE ratio of -5.06 and a beta of 1.95. The stock’s 50-day moving average price is $12.47 and its 200-day moving average price is $9.31.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 6th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The business had revenue of $5.33 million for the quarter, compared to analyst estimates of $6.82 million. Sell-side analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on EYPT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday. Chardan Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Royal Bank Of Canada initiated coverage on Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an “outperform” rating and a $28.00 price target on the stock. Finally, HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $26.86.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.